Well Referenced

Tag: Dual Agonist

Tirzepatide, a New Era of Dual-Targeted Treatment for Diabetes and Obesity: A Mini-Review

This 2022 mini-review discusses tirzepatide, a first-in-class dual agonist of glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors, approved for type 2 diabetes and obesity management. Tirzepatide significantly reduces glycemic levels, improves insulin sensitivity, and promotes weight loss exceeding 20%, along with favorable effects on lipid metabolism. Its design

Read More »
June 26, 2025 No Comments

Tirzepatide Once Weekly for the Treatment of Obesity

This 2022 randomized, double-blind, placebo-controlled trial evaluated the efficacy and safety of once-weekly subcutaneous tirzepatide (5 mg, 10 mg, or 15 mg) over 72 weeks in 2,539 adults with obesity or overweight with at least one weight-related comorbidity, excluding diabetes. Participants receiving tirzepatide experienced significant, dose-dependent weight reductions: −15.0% with

Read More »
June 26, 2025 No Comments